CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Exclusion Criteria

• •Therapy with CPI-613 prior to participating in this trial
• •Known hypersensitivity to 5-FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, brovavir, etc.)
• •History of hypersensitivity to active or inactive excipients of any component of treatment
• •Previous radiotherapy for central nervous system metastases
• •Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs
• •Serious medical illness that would potentially increase patients' risk for toxicity
• •Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease)
• •History of abdominal fistula or gastrointestinal perforation =\< 6 months prior to treatment with study drugs
• •Pregnant women, or women of child-bearing potential not using reliable means of contraception
• •Lactating females
• •Fertile men unwilling to practice contraceptive methods during the study period
• •Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
• •Unwilling or unable to follow protocol requirements
• •Symptomatic heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction or symptomatic congestive heart failure
• •Patients with a history of myocardial infarction that is \< 3 months prior to registration
• •Evidence of active infection, or serious infection within the past month
• •Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
• •Patients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment; steroid use for management of refractory pain or for contrast induced allergy is allowed
• •Requirement for immediate palliative treatment of any kind including surgery
• •Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of the patient